| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 28,944 | 15,801 |
| Net cash provided by (used in) investing activities | - | 0 |
| Increase/(decrease) in cash and cash equivalents | 16,909 | 8,260 |
| Cash and cash equivalents at beginning of period | 18,533 | - |
| Cash and cash equivalents at end of period | 35,442 | - |
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)